Stockreport

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com
PDF PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participantsP [Read more]